46 / 64
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 5, September/October 2020
266
AFRICA
Cardiology (ESC).
Eur Heart J
2016;
37
(36): 2768–2801.
4.
Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac
toxicity 4 to 20 years after completing anthracycline therapy.
J Am Med
Assoc
1991;
266
(12): 1672–1677.
5.
Von Hoff DD, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M,
Muggia FM. Risk factors for doxorubicin-induced congestive heart
failure.
Ann Intern Med
1979;
91
: 710–717.
6.
Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA.
Frequency and risk factors of subclinical cardiotoxicity after anthra-
cycline therapy in children: a systematic review.
Ann Oncol
2002;
13
(6):
819–829.
7.
Kremer LC, van Dalen EC, Offringa M, Voûte PA. Frequency and risk
factors of anthracycline-induced clinical heart failure in children: a
systematic review.
Ann Oncol
2002;
13
(4): 503–512.
8.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH,
et
al
. 2013 ACCF/AHA guideline for the management of heart failure: A
report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol
2013;
62
(16): e147–e239.
9.
Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular
target for primary prevention of anthracycline-induced cardiotoxicity.
Clin Pharmacol Ther
2014;
95
(1): 45–52.
10. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF,
et al.
Identification of the molecular basis of doxorubicin-induced cardiotox-
icity.
Nature Med
2012;
18
: 1639.
11. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y,
et al.
Juvenile
exposure to anthracyclines impairs cardiac progenitor cell function
and vascularization resulting in greater susceptibility to stress-induced
myocardial injury in adult mice.
Circulation
2010;
121
(5): 675–683.
12. Cardinale D, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M,
et al
. Early detection of anthracycline cardiotoxicity and improvement
with heart failure therapy.
Circulation
2015;
131
(22): 1981–1988.
13. Lee YT, Chan KK, Harris PA, Cohen JL. Distribution of adriamycin
in cancer patients: tissue uptakes, plasma concentration after IV and
hepatic IA administration.
Cancer
1980;
45
(9): 2231–2239.
14. Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick
TH. Use of myocardial strain imaging by echocardiography for the
early detection of cardiotoxicity in patients during and after cancer
chemotherapy: a systematic review.
J Am Coll Cardiol
2014;
63
(25, Part
A): 2751–2768.
15. Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K,
et al.
Anthracyclines induce early changes in left ventricular systolic and dias-
tolic function: A single centre study.
PLoS One
2017;
12
(4).
16. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH.
Use of speckle strain to assess left ventricular responses to cardiotoxic
chemotherapy and cardioprotection.
Eur Heart J Cardiovasc Imaging
2014;
15
(3): 324–331.
17. The Cancer Atlas. Risk-factors, infection.
https://canceratlas.cancer.org/risk-factors/infection/
18. Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte
I,
et al
. A recommended practical approach to the management of
anthracycline-based chemotherapy cardiotoxicity: an opinion paper of
the working group on drug cardiotoxicity and cardioprotection, Italian
Society of Cardiology.
J Cardiovasc Med
(Hagerstown) 2016;
17
(Suppl
1): S84–92.
19. Stefan DC. Cancer care in africa: an overview of resources.
J Glob Oncol
2015;
1
(1): 30–36.
20. SolomonK, Charles K.M, FredO, VictoriaW, JacksonO. Anthracycline-
induced cardiotoxicity in adult cancer patients: a prospective cohort
study from a specialized oncology treatment centre in Uganda.
Afr
Health Sci
2019;
19
(1): 1647–1656.
21. Ventura-Clapier R, Moulin M, Piquereau J, Zurlo G, Garnier A. Sex
differences in anthracycline cardiotoxicity.
Ital J Gender-Specific Med
2016;
2
(2): 47–54.
22. Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health
status among survivors of childhood cancer: does sex matter?
J Clin
Oncol
2007;
25
(28): 4477–4489.
23. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML,
Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment
for childhood cancer: the Pediatric Oncology Group experience.
J Clin
Oncol
1997;
15
(4): 1544–1552.
24. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in
African Americans.
J Natl Med Assoc
2004;
96
(2): 196–199.
25. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of
population and gender on chemotherapeutic agent-induced cytotoxicity.
Mol Cancer Ther
2007;
6
(1): 31–36.
26. Elalouani C, Benhmidoun MA, Rida H, AitRaiss M, Derhem N,
Elomrani A,
et al.
[Short and medium term cardiotoxicity of anthra-
cyclins: a prospective study].
Ann Cardiol Angeiol
(Paris) 2012;
61
(4):
257–266.
27. Pio M, Adoubi K, Adoh A, Didi-Kouko C, Anzouan-Kacou JB, Tegnan
A,
et al.
[Early detection of anthracyclines cardiotoxicity by tissue
Doppler echocardiography about 45 cases at Abidjan institute of cardi-
ology].
Ann Cardiol Angeiol
(Paris) 2013;
62
(1): 28–33.
28. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia
G,
et al.
Prognostic value of troponin I in cardiac risk stratification of
cancer patients undergoing high-dose chemotherapy.
Circulation
2004;
109
(22): 2749–2754.
29. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC,
et al.
Longitudinal changes in multiple biomarkers are associated with cardio-
toxicity in breast cancer patients treated with doxorubicin, taxanes, and
trastuzumab.
Clin Chem
2015.
61
(9): 1164–1172.